RNCS Free Assessment
FAQ

Frequently Asked Questions

Quality Management System
What is the difference between ISO 9001 and ISO 13485?

ISO 9001 is a general quality standard for any industry, focused on customer satisfaction and continual improvement. ISO 13485 is built for medical devices and focuses on regulatory compliance, product safety and effectiveness. It adds requirements ISO 9001 does not have: risk management across the product lifecycle, design controls and design history files, sterile and implantable device controls, process validation, traceability, complaint handling and regulatory reporting. ISO 9001 certification alone is not accepted by device regulators; ISO 13485 is.

Is ISO 13485 certification mandatory?

No law mandates the certificate itself, but in practice you cannot sell most devices without an ISO 13485-compliant QMS:

  • EU MDR: Article 10(9) requires a QMS; Notified Bodies assess it against EN ISO 13485 for all devices other than self-certified Class I.
  • USA: the Quality Management System Regulation (QMSR), effective 2 February 2026, incorporates ISO 13485:2016 by reference into 21 CFR Part 820. FDA inspects against it but does not issue certificates, and an ISO certificate does not exempt you from FDA inspection.
  • Saudi Arabia: SFDA expects an ISO 13485 certificate as part of the MDMA technical file.
  • India: the Medical Devices Rules, 2017 (Fifth Schedule) set out QMS requirements aligned with ISO 13485, which are verified during licensing audits and inspections.
How long does ISO 13485 certification take, and how long is it valid?

Most small and mid-sized organizations need 6–12 months from gap analysis to certificate. The biggest variable is how much of your QMS already exists and how quickly you can generate implementation records. The certificate is valid for three years, with annual surveillance audits and a recertification audit before expiry.

What is MDSAP and should we join?

The Medical Device Single Audit Program lets one audit by an MDSAP-recognized auditing organization satisfy the QMS requirements of five regulators: USA (FDA), Canada (Health Canada), Brazil (ANVISA), Australia (TGA) and Japan (MHLW/PMDA). MDSAP is mandatory for Canada and, in the US, FDA accepts MDSAP audit reports in place of routine FDA inspections. If you sell or plan to sell in two or more of these markets, MDSAP usually saves audit days and cost.

Internal Audit
What is an Internal Audit?

An internal audit is a systematic, independent examination of your organization’s Quality Management System (QMS). It helps confirm that your QMS meets ISO 13485 requirements, ensures compliance with regulatory frameworks such as FDA QSR/QMSR and EU MDR/IVDR, checks alignment with your own documented procedures, and verifies that the system is effectively implemented and maintained.

How often are internal audits required?

None of the three main frameworks — ISO 13485, FDA QMSR, or EU MDR — prescribe a fixed number of audits per year. Instead, they require a risk-based, planned audit program.

  • ISO 13485 (Clause 8.2.4) requires audits "at planned intervals," with frequency, scope, and methods determined by the importance and risk of the process, area, or product line, and by results of previous audits.
  • FDA QMSR incorporates ISO 13485:2016 and reinforces internal audit as a management-controlled process, so it inherits ISO's "planned intervals" requirement rather than imposing a separate schedule.
  • EU MDR doesn't set an internal audit frequency directly, but Article 10(9) requires manufacturers to maintain a QMS covering internal audits as part of ongoing conformity.

Bottomline: While regulations do not mandate a fixed schedule, the industry standard is to conduct at least one full-cycle internal audit each year. In addition, organizations typically perform more frequent targeted or process-specific audits for higher-risk areas to ensure ongoing compliance and effectiveness.

Can we outsource our entire internal audit program?

Yes — this is explicitly permitted under ISO 13485, and it's a common approach for smaller or resource-constrained organizations. The standard requires only that auditors be independent of the area being audited and doesn't require them to be employees.

Clause 8.2.4 is satisfied whether the audit is conducted by trained internal staff or by qualified external/contracted auditors.

A few things to keep in mind when fully outsourcing:

  • You must retain ownership of the program: Management is still accountable for ensuring audits happen at planned intervals, that findings are acted on, and that the audit program feeds into management review. Outsourcing the execution doesn't outsource the responsibility.
  • The audit schedule, scope, and criteria should still reflect your risk profile: A good, outsourced partner will build this with you rather than applying a generic template.
  • CAPA ownership stays internal: External auditors identify and help classify findings and can support root cause analysis, but corrective actions are implemented and verified by your organization.
  • FDA and EU MDR treat outsourced audits the same way — QMSR (which incorporates ISO 13485:2016) and EU MDR both expect a documented, risk-based audit program with independent auditors; neither requires those auditors to be in-house. Since FDA now has inspection authority over internal audit reports, having experienced external auditors can actually strengthen your position by ensuring findings meet the rigor regulators expect.

So the engagement can range from a single mock audit, to a fully outsourced annual program, to a hybrid where we cover specialized or higher-risk areas while your team handles the rest.

What's the difference between an internal audit and a supplier audit?

They're both audits under your QMS, but they look at different things and serve different purposes:

Internal AuditSupplier Audit
ScopeYour own organization's QMS, processes, and departmentsAn external supplier's or subcontractor's quality system and processes
Regulatory driverISO 13485 Clause 8.2.4 (mandatory, planned intervals)ISO 13485 Clause 7.4 (purchasing controls) — audits are a common but not universally mandatory verification method, depending on supplier risk
PurposeVerify your own QMS conforms to the standard, regulatory requirements, and your documented proceduresVerify a supplier's ability to consistently deliver conforming product/service and meet your specifications and quality requirements
Who's assessedYour process owners, departments, recordsSupplier's facility, processes, records, and sometimes their own sub-tier suppliers
Frequency driverRisk and importance of your internal processesRisk classification of the supplier/component (critical suppliers audited more frequently) and their performance history
Outcome feeds intoYour management review, your CAPA systemYour Approved Supplier List, supplier scorecards/ratings, and your own CAPA if supplier issues affect your product
Typical trigger for immediate auditScheduled interval, or a systemic internal issue (e.g., recurring CAPA in one area)Supplier quality complaints, incoming inspection failures, or a change in supplier's process/location
Can you audit against MDR and FDA simultaneously?

Yes — this is now more straightforward than it used to be.

Since the FDA QMSR became effective February 2, 2026, harmonizing FDA's device quality requirements with ISO 13485:2016, a single audit built on an ISO 13485 checklist covers majority of both FDA and EU MDR expectations at once. The requirements that remain distinct to each region can be layered in:

  • FDA-retained provisions not fully covered by ISO 13485 alone — Unique Device Identification (21 CFR 830), Medical Device Reporting (803), Reports of Corrections & Removals (806), and Medical Device Tracking (821) — sometimes referred to as "Other Applicable FDA Requirements.
  • EU MDR-specific elements — post-market surveillance (PMS) and PMCF processes, vigilance reporting, EUDAMED obligations, UDI under the EU system, and Authorized Representative/Person Responsible for Regulatory Compliance requirements.

So, the audit is one integrated exercise against a common ISO 13485 backbone, with region-specific checklists applied on top — not two entirely separate audits.

How long does a typical audit take?

This depends on organization size, number of sites, product complexity, and scope, but as a general guide:

  • Small/single-site manufacturer, full QMS audit: Typically, 1–2 days on-site (plus preparation and reporting time before/after).
  • Mid-size manufacturer, multi-process audit: Typically, 3–5 days.
  • Large or multi-site organization, full-cycle audit: Can extend to 1–2 weeks, sometimes staged across multiple visits over the year to cover the full clause/process schedule.
  • Targeted/process audits (e.g., just CAPA or just design controls): Usually a half-day to 1 day.

Total elapsed time — including planning, document review, on-site or remote execution, and the final report — is usually 2–4 weeks from kick-off to report delivery for a full audit, even though on-site time itself is much shorter.

What happens if you find a major non-conformance?

A major non-conformance indicates a systemic failure to meet a regulatory or standard requirement, unlike a minor, isolated lapse. The typical process is:

  • Immediate documentation with objective evidence, citing the clause or procedure violated and justification for classifying it as major.
  • Communication at the closing meeting to process owners and management — findings are not withheld until the final report.
  • Root cause analysis is required (superficial fixes are not accepted). The organization must investigate why the failure occurred, not just what happened.
  • CAPA initiation under the organization’s CAPA procedure, with a defined corrective action plan and timeline.
  • Effectiveness verification through follow-up audit or review to confirm the corrective action resolved the issue and prevented recurrence, before closure.
  • Formal QMS recordkeeping, feeding into management review. Under FDA QMSR, this is significant because FDA now has authority to inspect internal audit reports directly (previously confidential), so unresolved or poorly documented major findings pose inspection risk. Similarly, EU MDR notified bodies expect evidence that internal audits drive genuine corrective action, not just paperwork.

Bottom line: Leaving a major non-conformance unresolved internally is far preferable to having the same issue surface during an FDA inspection or Notified Body surveillance audit — which underscores the value of a rigorous internal audit program.

Clinical investigation
What is the difference between Clinical Evaluation vs. Clinical Investigation?

Clinical evaluation is the continuous process of collecting and critically assessing all available clinical data on a device to show that it is safe, performs as intended and has an acceptable benefit-risk profile. Its output is the Clinical Evaluation Report (CER), which every device class needs under the EU MDR.

A clinical investigation is one possible source of that data: a planned study in human subjects, run to ISO 14155, that generates new clinical data.

Clinical EvaluationClinical Investigation
What it isAn ongoing assessment of all clinical dataA prospective study generating new data
Required forEvery device, every class (MDR Article 61)Only when existing data are insufficient (always for most Class III and implantables)
Data sourcesLiterature, equivalent devices, PMS/PMCF data, investigationsSubjects enrolled under a protocol
OutputClinical Evaluation Plan and Report (CEP/CER)CIP and Clinical Investigation Report (CIR)
Governing guidanceMDR Art. 61 & Annex XIV, MEDDEV 2.7/1 Rev. 4, MDCG 2020-5/6/13MDR Art. 62–82 & Annex XV, ISO 14155
TimingBefore certification, then updated throughout the device lifecycleA defined start and end
In short: clinical evaluation is the verdict; a clinical investigation is one of the pieces of evidence that can support it.
Do we need a clinical investigation or can literature suffice?

Often literature is enough, but not always. It depends on the device class, novelty and how much good-quality data already exist.

  • Literature and existing data may be enough when: the device uses well-established technology; you can show equivalence to a device with sufficient clinical data (with access to that device's technical documentation for Class III and implantables); or robust PMS data exist from years of safe use.
  • A clinical investigation is generally required when: the device is Class III or implantable (MDR Article 61(4)), unless the exemptions in Article 61(4)–(6) apply; the device is novel, with new materials, mechanisms or indications; equivalence cannot be demonstrated; or the literature does not cover your specific claims, patient population or safety endpoints.
  • Notified Bodies have become stricter: under the MDR, equivalence must be shown across technical, biological and clinical characteristics, and "similar" devices are no longer enough.

Our recommendation: start with a clinical evidence gap analysis. We assess what you already have, what your claims require, and whether a targeted PMCF study, rather than a full pre-market investigation, could close the gap. This single step often saves months and significant cost.

CE Certification under EU MDR
What are the steps to obtain CE marking under the EU MDR?
  • Confirm the product is a medical device and determine its class (Annex VIII, 22 rules: Class I, IIa, IIb, III).
  • Implement a QMS (ISO 13485) including the MDR-specific processes: PMS, vigilance, PRRC, UDI.
  • Prepare technical documentation (Annexes II and III), including GSPR checklist, risk management (ISO 14971), verification and validation, and the Clinical Evaluation Report.
  • Appoint an EU Authorized Representative if you are outside the EU, and a Person Responsible for Regulatory Compliance (PRRC).
  • Select a Notified Body designated for your device codes (NANDO database) and complete the conformity assessment (Annex IX, X or XI).
  • Receive the CE certificate, sign the EU Declaration of Conformity, affix the CE mark and register your devices in EUDAMED.
How long does CE certification take and what does it cost?

For Class IIa–III devices, plan for 12–18 months from Notified Body application to certificate, and longer for novel Class III devices. Notified Body fees vary widely with device class, number of devices and audit days, so request quotes from two or three Notified Bodies. Class I self-certified devices can be ready in 3–6 months once the documentation is in place.

Do I need a Notified Body for a Class I device?

Not for standard Class I devices. The manufacturer self-declares conformity. However, Class Is (sterile), Class Im (measuring function) and Class Ir (reusable surgical instruments) need a Notified Body for those specific aspects. All Class I devices still need full technical documentation, a CER, PMS and EUDAMED registration.

What is a PRRC and do we need one?

Under MDR Article 15, every manufacturer must have at least one Person Responsible for Regulatory Compliance with documented expertise. Micro and small enterprises can use an external PRRC who is permanently and continuously available. Non-EU manufacturers' Authorized Representatives must also have a PRRC.

Our MDD certificate has expired. Can we still sell in the EU?

Possibly. Regulation (EU) 2023/607 extended the transition until 31 December 2027 (Class III and Class IIb implantables) or 31 December 2028 (other classes), but only if you had an MDR-compliant QMS in place by 26 May 2024, lodged a formal MDR application by 26 May 2024, signed a written agreement with a Notified Body by 26 September 2024, and have made no significant changes to the device. If you missed these conditions, contact us urgently to review your options.

SFDA Registration – Saudi Arabia
What is an MDMA, and does every device need one?

The Medical Device Marketing Authorization (MDMA) is the SFDA approval needed before a medical device or IVD can be imported, distributed or sold in Saudi Arabia. Most devices need an MDMA through the full Technical File Assessment route. Certain low-risk Class A devices may instead be listed through the Medical Device Listing route. We confirm the right route during classification.

What documents are required for SFDA registration?

Typical MDMA technical file contents include: Authorized Representative agreement and licence details; device description and classification rationale; ISO 13485 certificate; Declaration of Conformity; essential principles/GSPR checklist; design and manufacturing information; risk management file; verification and validation reports (biocompatibility, sterilization, electrical safety, software); clinical evidence (CER or clinical data); labeling and IFU (Arabic where required); post-market surveillance plan; and reference-market approvals such as CE certificates or FDA clearance, where available.

How long does SFDA approval take?

SFDA's official review timeframe is 35 working days, but the clock stops while you respond to questions. In practice, allow 3–6 months from submission to MDMA for a complete file, plus 1–2 months beforehand to appoint your AR and prepare the file.

How long is an MDMA valid?

Up to three years, typically aligned with the validity of your supporting certificates (e.g., ISO 13485 or CE certificate). Start the renewal at least 3–6 months before expiry to avoid gaps in market access.

Do importers and distributors in Saudi Arabia need their own licence?

Yes. Local companies that import, distribute or store medical devices need a Medical Device Establishment Licence (MDEL) from SFDA, separate from the manufacturer's MDMA and the AR licence.

CDSCO Registration – India
Are all medical devices regulated in India now?

Yes. Under the Medical Devices Rules, 2017, licensing became mandatory in phases: Class A and B devices from 1 October 2022, and Class C and D devices from 1 October 2023. Today, all medical devices and IVDs imported, manufactured, sold or distributed in India need the appropriate CDSCO licence.

What documents are required for an MD-14 import licence application?
  • Power of Attorney from the manufacturer to the Indian Authorized Agent (notarized/apostilled as required)
  • Free Sale Certificate from the country of origin, or approval from a reference country (US, EU, UK, Canada, Australia, Japan)
  • ISO 13485 certificate and, where applicable, CE certificate or FDA clearance
  • Device Master File and Plant Master File in the format of the Fourth Schedule
  • Labels and IFU meeting Indian labeling rules, including importer name, address and licence number
  • Test reports, essential principles checklist, and a Clinical Evaluation Report for Class C and D devices
  • Authorized Agent's wholesale/sale licence or registration, and undertakings as per the checklist
How long does CDSCO approval take?

The Rules allow the Central Licensing Authority up to nine months to decide on an import licence application. Complete, well-organized dossiers for Class A and B devices are often approved sooner; Class C and D devices take longer and may involve a site inspection or MDAC review. Fast, complete answers to deficiency letters are the most important factor you can control.

Can a foreign manufacturer apply directly to CDSCO?

No. The application must be filed through the SUGAM/National Single Window portal by an Indian Authorized Agent, i.e., an Indian company with a valid manufacturing licence or a licence/registration to sell medical devices. That agent also becomes responsible for post-market obligations, including complaint handling, field safety notices and recalls.

Is clinical data from other countries accepted by CDSCO?

Generally, yes. For devices already approved in reference countries, CDSCO usually accepts existing clinical data and may waive a local clinical investigation. For novel devices without a predicate, or where Indian population data are needed, CDSCO may require a clinical investigation in India (Form MD-22).

EUDAMED
What is EUDAMED?

EUDAMED is the European Database on Medical Devices created under the EU MDR and IVDR. It gives regulators, Notified Bodies, companies and the public a single source of information on economic operators, devices, certificates, clinical investigations, vigilance and market surveillance. It is organized into six modules: Actor registration; UDI/Device registration; Notified Bodies & Certificates; Clinical Investigations & Performance Studies; Vigilance & Post-Market Surveillance; and Market Surveillance.

When is EUDAMED mandatory?

Following Commission Decision (EU) 2025/2371 and Regulation (EU) 2024/1860, four modules became mandatory on 28 May 2026: Actor registration, UDI/Device registration, Notified Bodies & Certificates, and Market Surveillance. Key transition dates:

  • New devices placed on the market from 28 May 2026 must be registered before being placed on the market.
  • Devices already on the market before that date (including legacy devices) must be registered by 28 November 2026.
  • Notified Bodies must upload existing certificate information by 28 May 2027.

The Vigilance and Clinical Investigation modules will become mandatory later, once declared functional.

What is an SRN and how do I get one?

A Single Registration Number (SRN) is the unique ID issued to manufacturers, Authorized Representatives and importers when they register in the EUDAMED Actor module. The competent authority of the Member State where you (or your EU AR) are established validates your registration. You need an SRN before you can apply to a Notified Body or register devices, so it is usually the first step.

What device information must be registered?

For each device: the Basic UDI-DI and UDI-DI, device name and model, risk class, EMDN nomenclature code, intended purpose, sterility and implantable status, whether it contains substances such as medicinal products or CMR/endocrine disrupting substances, certificate details, and the SRN of the manufacturer and AR. For Class III and implantable devices, the Summary of Safety and Clinical Performance (SSCP) is also published.

Post-Market Surveillance
What is post-market surveillance (PMS), and why does it matter?

PMS is the proactive, systematic process of collecting and reviewing experience from devices already on the market, including complaints, incidents, literature, registries, user feedback and PMCF data, to confirm they remain safe and perform as intended, and to trigger corrective action when they do not. Under the EU MDR, PMS is a legal obligation for every device class and is one of the areas Notified Bodies examine most closely.

What PMS documents are required under the EU MDR?
DocumentRequired forFrequency
PMS Plan (Annex III)All classesMaintained as part of the technical documentation
PMS Report (PMSR, Art. 85)Class IUpdated when necessary
Periodic Safety Update Report (PSUR, Art. 86)Class IIaAt least every 2 years
PSURClass IIb and IIIAt least annually; Class III and implantable PSURs are reviewed by the Notified Body
PMCF Plan and Evaluation ReportAll classes (or justified absence)Updated with the CER
What are the vigilance reporting timelines in the EU?

Serious incidents must be reported to the competent authority immediately after a causal relationship is established or reasonably possible, and no later than 15 days after becoming aware; 10 days for death or unanticipated serious deterioration in health; and 2 days for a serious public health threat. Field Safety Corrective Actions must be reported before they are carried out (unless urgent), and statistically significant increases in non-serious incidents must be trend-reported (Article 88).

How does PMS work in the US, Saudi Arabia and India?
  • USA: Medical Device Reporting (21 CFR 803). Deaths and serious injuries must be reported within 30 calendar days, or 5 working days where remedial action is needed to prevent unreasonable risk. Corrections and removals are reported under 21 CFR 806 within 10 working days.
  • Saudi Arabia: adverse event and FSCA reporting to the SFDA's NCMDR, and a distribution tracking system maintained by manufacturers, ARs and distributors.
  • India: complaint handling, field safety corrective actions and recall obligations under the Medical Devices Rules, 2017, with adverse events reported through CDSCO and the Materiovigilance Programme of India (MvPI).
Can PMS be outsourced?

Yes. Many manufacturers outsource literature monitoring, complaint trending, PSUR/PMSR writing and PMCF evaluation. You remain legally responsible, but an experienced partner keeps the process running on schedule and to Notified Body expectations. We offer PMS as a retainer service with a fixed annual calendar of deliverables.

Clinical Evaluation Reports (CERs)
What is a Clinical Evaluation Report?

A CER documents the clinical evaluation of a device: the critical appraisal of clinical data from literature, equivalent devices, clinical investigations and post-market experience, showing that the device meets the relevant GSPRs for safety and performance and has an acceptable benefit-risk profile. It is required for every device class under the EU MDR (Article 61 and Annex XIV) and requested by CDSCO for Class C and D devices and by SFDA as part of clinical evidence.

What does a CER contain?

A Clinical Evaluation Plan; device description and intended purpose; state-of-the-art analysis (current treatment options and benchmarks); equivalence demonstration, if used; the literature search protocol and results; appraisal and analysis of all clinical data; benefit-risk analysis; PMS and PMCF data; residual risks and gaps; and conclusions signed by qualified evaluators. For Class III and implantables, the CER also underpins the Summary of Safety and Clinical Performance (SSCP).

How often must a CER be updated?

The CER is a living document. Under the MDR it must be updated with PMS data. In practice, Notified Bodies expect annual updates for Class III and implantable devices (in line with the PSUR), and updates every 2–5 years for lower-risk devices, justified in the CEP. Update it sooner if new safety information, a design change or a new indication arises.

Who can write a CER?

MEDDEV 2.7/1 Rev. 4 expects evaluators to have a relevant degree plus five years of professional experience (or ten years without a degree) in research methodology, device technology and the relevant clinical field, with a signed declaration of interests. Our CERs are written by experienced medical writers and reviewed by clinical and biostatistical experts.

Why do Notified Bodies reject CERs?

The most common findings are: an insufficient state-of-the-art section; equivalence claims without enough technical, biological and clinical comparison; literature searches that are not reproducible; data that do not support every claim in the IFU; missing quantitative safety and performance acceptance criteria; and a PMCF plan that does not address identified gaps. We run a Notified Body-style review against these points before submission.

Contact us today

Tell us about your device and target market. Our regulatory specialist, not a salesperson, will reply within one business day.

Get Your Free Regulatory Assessment